MIRM Mirum Pharmaceuticals (MIRM) Q1 FY26 earnings call
Mirum Pharmaceuticals delivered a strong first quarter, marked by robust commercial performance of its rare liver disease portfolio and strategic expansion into rare genetic diseases. The company raised its full-year revenue guidance, reflecting continued demand for LIVMARLI and bile acid medicines. Significant pipeline advancements, including positive clinical readouts for volixibat and brelovitug, and the acquisition of zilurgisertib for FOP, underscore Mirum's commitment to building a financially self-sustaining business with multiple growth drivers across rare liver and genetic disease pla
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.